NASDAQ$VXRT
Vaxart Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Announced second quarter 2023 financial results and provided business update.
Vaxart reported a revenue of $1.4 million and a net loss of $22.6 million for the second quarter of 2023. The company's cash runway has been extended into Q3 2024.
- Reported positive preliminary topline data from Phase 2 bivalent norovirus vaccine candidate.
- Advanced oral pill vaccine programs and delivered on planned timelines.
- Anticipate reporting topline data from GI.1 norovirus challenge study during the third quarter.
- Ended the second quarter with $67.9 million in cash, cash equivalents, restricted cash and marketable securities.
Headline financials
Revenue & EPS history
Vaxart · Revenue · Quarterly
$1.36M
Forward guidance
Vaxart continues to make progress on its anticipated milestones in 2023.
Tailwinds
- Topline data from the ongoing Phase 2 challenge study of Vaxart’s GI.1 norovirus vaccine candidate is expected in Q3 2023.
- Initiation of a Bill & Melinda Gates Foundation-funded clinical trial to evaluate the ability of Vaxart’s norovirus vaccine candidate to induce antibodies in breast milk and transfer of antibodies to young infants.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
-1.4%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-3.7%
Avg return
30 days after
37%
23 / 62 earnings
Positive
+22.7%
Q1 2024
Best reaction
-23.1%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.4% | -8.8% | -19.5% | |
| Q4 2025 | -13.0% | -14.9% | -14.9% | |
| Q3 2025 | +11.6% | +5.4% | +0.0% | |
| Q1 2025 | -0.7% | +19.0% | +66.7% | |
| Q4 2024 | -9.1% | -19.3% | -40.4% | |
| Q3 2024 | -12.8% | -15.3% | -18.1% | |
| Q2 2024 | -2.7% | +0.0% | +48.3% | |
| Q1 2024 | +22.7% | +35.2% | +7.0% | |
| Q4 2023 | -4.4% | +2.7% | -19.5% | |
| Q3 2023 | +8.4% | +12.3% | +12.3% | |
| Q2 2023 | +1.3% | -3.9% | +9.2% | |
| Q1 2023 | +0.0% | +0.0% | +44.8% | |
| Q4 2022 | +0.0% | -10.1% | -16.5% | |
| Q3 2022 | -11.9% | +16.1% | -20.3% | |
| Q2 2022 | +3.4% | +1.2% | -31.1% | |
| Q1 2022 | -9.6% | -6.2% | +5.1% | |
| Q4 2021 | +18.9% | +12.8% | +13.9% | |
| Q3 2021 | -8.0% | -6.7% | -12.9% | |
| Q2 2021 | +5.4% | +11.6% | +4.9% | |
| Q1 2021 | -18.7% | -33.2% | -31.7% | |
| Q4 2020 | -2.6% | -2.7% | -18.4% | |
| Q3 2020 | +10.0% | +23.0% | +61.4% | |
| Q2 2020 | -4.9% | +11.3% | -49.0% | |
| Q1 2020 | +1.1% | -2.1% | -20.7% | |
| Q4 2019 | -23.1% | -27.4% | -15.0% | |
| Q3 2019 | -2.9% | -11.4% | -8.6% | |
| Q2 2019 | +21.1% | +17.5% | +22.8% | |
| Q1 2019 | +8.5% | +9.9% | -8.5% | |
| Q4 2018 | -9.5% | -12.2% | -25.3% | |
| Q3 2018 | -15.8% | -12.1% | +0.7% | |
| Q2 2018 | +0.6% | -1.0% | +0.3% | |
| Q1 2018 | -5.3% | -1.8% | +1.8% | |
| Q4 2017 | +4.8% | +0.0% | +9.5% | |
| Q3 2017 | -2.0% | +0.0% | -6.0% | |
| Q2 2017 | -1.7% | -1.7% | -46.6% | |
| Q1 2017 | -8.3% | -4.1% | -33.2% | |
| Q4 2016 | +0.0% | +11.3% | +12.0% | |
| Q3 2016 | -3.1% | — | — | |
| Q2 2016 | -15.2% | — | — | |
| Q1 2016 | +7.6% | — | — | |
| Q4 2015 | -4.6% | — | — | |
| Q3 2015 | -3.1% | — | — | |
| Q2 2015 | -2.4% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q1 2015 | -0.8% | — | — | |
| Q3 2014 | -6.3% | — | — | |
| Q2 2014 | +0.2% | — | — | |
| Q1 2014 | +1.5% | — | — | |
| Q4 2013 | +1.5% | — | — | |
| Q3 2013 | -0.8% | — | — | |
| Q2 2013 | +2.6% | — | — | |
| Q1 2013 | +0.6% | — | — | |
| Q4 2012 | -1.8% | — | — | |
| Q3 2012 | +1.1% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | -1.0% | — | — | |
| Q2 2010 | -5.2% | — | — | |
| Q2 2011 | -5.2% | — | — | |
| Q1 2011 | +0.9% | — | — | |
| Q4 2010 | +2.0% | — | — | |
| Q3 2010 | +0.2% | — | — | |
| Q1 2010 | -7.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro